AK1910
/ SBI Biotech, Asahi Kasei Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 19, 2020
Asahi Kasei Pharma introduces SBI Biotech's therapeutic agent for autoimmune diseases [Google Translation]
(AnswersNews)
- "Asahi Kasei Pharma announced on March 19 that it has entered into an exclusive license agreement with SBI Biotech to acquire global development, manufacturing and marketing rights for the autoimmune disease drug SBI-3150 being developed....Asahi Kasei Pharma will pay a one-time payment for the contract and will also pay development milestones and sales royalties."
Licensing / partnership
1 to 1
Of
1
Go to page
1